Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pollock

Showing results (881-890 of 896) with videos related to

Pageof 90
Sort By:
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
Plos Genetics|September 9, 2011
Predisposition to cancer caused by genetic and functional defects of mammalian Atad5Daphne W Bell, Nilabja Sikdar, Kyoo-Young Lee, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Plos One|August 17, 2016
Assessing the Cost of Global Biodiversity and Conservation KnowledgeDiego Juffe-Bignoli, Thomas M Brooks, Stuart H M Butchart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Plos One|November 8, 2023
A multi-taxon analysis of European Red Lists reveals major threats to biodiversityAxel Hochkirch, Melanie Bilz, Catarina C Ferreira, et al.
Pageof 90

Showing results (881-890 of 896) with videos related to

Sort By:
Pageof 90
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
Plos Genetics|September 9, 2011
Predisposition to cancer caused by genetic and functional defects of mammalian Atad5Daphne W Bell, Nilabja Sikdar, Kyoo-Young Lee, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Plos One|August 17, 2016
Assessing the Cost of Global Biodiversity and Conservation KnowledgeDiego Juffe-Bignoli, Thomas M Brooks, Stuart H M Butchart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Plos One|November 8, 2023
A multi-taxon analysis of European Red Lists reveals major threats to biodiversityAxel Hochkirch, Melanie Bilz, Catarina C Ferreira, et al.
Pageof 90